According to MarketBeat, Zymeworks has a consensus rating of “Moderate Buy” and an average target price of $12.

Source: https://www.etfdailynews.com/2023/09/11/corton-capital-inc-acquires-new-shares-in-zymeworks-inc-nysezyme/

Finally, if Jazz choses to continue the collaboration after results from HERIZON-BTC-01 are posted, Zymeworks will receive an additional $325 million upfront payout.

Source: https://seekingalpha.com/article/4568641-revisiting-zymeworks-after-big-licensing-deal?source=feed_all_articles

Frazier Life Sciences Management L.P. acquired a new stake in Zymeworks Inc. () during the 4th quarter, Holdings Channel.com reports.

Source: https://www.etfdailynews.com/2023/05/01/frazier-life-sciences-management-l-p-takes-4-80-million-position-in-zymeworks-inc-nysezyme/

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer.

Source: https://www.etfdailynews.com/2023/01/26/allspring-global-investments-holdings-llc-grows-position-in-zymeworks-inc-nysezyme/